|
|
|
|
|
Daclizumab
drug data and news
Daclizumab drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Daclizumab | ||
| Brand Names/Synonyms | Ig gamma-1 chain C region; humanized antiCD25; anti-IL-2; Zenapax (Hoffmann-La Roche Inc) | ||
| Indication | For prevention of renal transplant rejection | ||
| Sponsored links | Description | Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. | |
| Pharmacology | Zenapax functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection. | ||
| Mechanism Of Action | Zenepax binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. | ||
| Daclizumab News (When available) |
PDL's Potent Pick-Me-Up Feb 27, 2006 PDL BioPharma Announces Fourth Quarter and Full Year 2005 ... Feb 27, 2006 PDL BioPharma Set For Years Of Growth Feb 24, 2006 Tysabri Events For Biogen Idec Overshadow Year-End Figures Feb 17, 2006 | ||
| Dosage Forms | LIQUID | ||
| Drug_Category | Immunosupressants; Immunomodulatory Agents; unclassified therapeutic agents (92:00.00) | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Humanized anti-CD25 antibody | ||
| Chemical Formula | C6332H9808N1678O1989S42 >Humanized Anti-CD25 Light Chain 1 >Humanized Anti-CD25 Heavy Chain 2 >Humanized Anti-CD25 Light Chain 2 | ||
| Molecular Weight | 142612.1 | ||
| Smiles String | Not Available | ||
| Melting Point | 61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000). | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | -0.437 | ||
| Isoelectric Point | 8.46 | ||
| Biotransformation | Most likely removed by opsonization via the reticuloendothelial system when bound to lymphocytes. | ||
| Half Life | 11-38 days | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Daclizumab.html http://www.rxlist.com/cgi/generic3/zenapax.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00007 | ||
| CAS Registry Number | 152923-56-3 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA449198 | ||
| SwissProt ID | IGHG1_HUMAN (P01857) | ||
| GenBank ID | J00228 | ||
| Drug ID Number [DIN] | 2241473 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |